^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ensituximab (NEO-102)

    i
    Other names: NEO-102, NEO 101, NEO101, NPC 1C, NPC-1C, NPC1-C, NEO-101
    Associations

    News

    Trials
    Company:
    Precision Biologics
    Drug class:
    Neoplasm antigen inhibitor
    Associations

    News

    Trials
    10ms
    QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=81, Terminated, Precision Biologics, Inc | Phase classification: P2 --> P1/2
    Phase classification
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • ensituximab (NEO-102)
    3years
    Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. (PubMed, JAMA Netw Open)
    Treatment options are limited for patients with advanced pancreatic ductal adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), with such individuals commonly being treated with gemcitabine and nab-paclitaxel. These data provide a benchmark for future trials investigating second-line treatment of PDAC. ClinicalTrials.gov Identifier: NCT01834235.
    Clinical • Journal • Metastases
    |
    CA 19-9 (Cancer antigen 19-9) • MUC5AC (Mucin 5AC)
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • ensituximab (NEO-102)
    over4years
    Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. (PubMed, Cancers (Basel))
    NPC-1C and PAM4 antibody reactive epitopes on MUC5AC are immunogenic and could represent specific changes on the native MUC5AC glycoprotein linked to carcinogenesis. It was never studied to predict treatment response.
    Clinical • Review • Journal
    |
    MUC5AC (Mucin 5AC)
    |
    MUC5AC expression
    |
    ensituximab (NEO-102)
    almost6years
    Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. (PubMed, Clin Cancer Res)
    Ensituximab was well tolerated and demonstrated modest antitumor activity in patients with heavily pretreated refractory CRC.
    Clinical • P2 data • Journal
    |
    MUC5AC (Mucin 5AC)
    |
    ensituximab (NEO-102)